Alchemab Raises $82 Million to Advance Antibody Therapeutics in Neurodegeneration and Cancer
Alchemab Raises $82 Million to Advance Antibody Therapeutics in Neurodegeneration and Cancer Share Rare Daily Staff Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, said it closed an $82 million (£60 million) series A financing round. RA Capital Management led the financing, with participation by an international syndicate that included Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors, and the Dementia Discovery Fund. The company was ...
Source: globalgenes.org